40 results on '"Triest, B."'
Search Results
2. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism
3. PD-0798 Development and results of a patient-reported treatment experience questionnaire on a 1.5 T MR-Linac
4. OC-0692: Phase 1 study of olaparib as radiosensitizer for locally advanced non-small cell lung cancer
5. OC-0438: Clinical pharmacodynamics support biological effectivity of low dose olaparib as radiosensitizer
6. PD-0189: Individualized Beam Angle Selection for MRLinac Treatment of Rectal Cancer Patients
7. PD-0071: The MOMENTUM study, an international registry of patients treated on an MR-linac: 9-month experience
8. PD-0070: Contour propagation for online treatment of rectal cancer using MR guidance
9. PV-0426 First system for fully automated multicriterial planning for an MR-Linac applied to rectal cancer
10. EP-2115: MRI visibility of gold fiducial markers for image-guided radiotherapy for rectal cancer
11. PO-0963: MR-Linac: first experience with library of plan technique for rectal cancer patients
12. OC-0608: Radiotherapy quality assurance program for the STAR-TReC trial; planning results of Dutch centers
13. OC-0522: First clinical results of a library of plans strategy in radiotherapy of rectal cancer
14. OC-0280: Proctitis after brachytherapy for rectal cancer: clinical and dosimetric factors - The HERBERT study
15. EP-1784: Needle use in cervical cancer brachytherapy using the Utrecht applicator: a single center experience
16. PO-0838: Treatment planning for the MR-linac: plan quality compared with current clinical practice
17. PV-0328: Factors associated with complete response after brachytherapy for rectal cancer; the HERBERT study
18. Feasibility Study of Erlotinib (tarcevaR) Plus Radiotherapy in Patients with Locally Advanced or Recurrent Rectal Carcinoma
19. 2131: Evaluation of 4DCT-Based IMRT and Respiratory Gating in Locally Advanced Pancreatic Carcinoma
20. 888P Phase I study of olaparib combined with loco-regional radiotherapy in patients with head and neck squamous cell carcinoma.
21. SP-0297 - Results of phase I trials combining PARP inhibition and radiotherapy in multiple sites.
22. PD-0427: A pharmacodynamic assay to assess the radiosensitizing potential of PARP inhibitors in clinical trials.
23. PD-0129: GTV and CTV in prostate cancer: distance and size of satellites relative to the index lesion.
24. The Patterns of Care, Tolerability and Safety in the First Year of a Novel High Field MR-Linac.
25. 1845PSafety, clinical activity and pharmacological biomarker evaluation of the DNA-dependent protein kinase (DNA-PK) inhibitor M3814: Results from two phase I trials.
26. SP-0208: Validation of imaging with histology: implications for dose prescriptions.
27. OC-0470: Library of plans in radiotherapy of rectal cancer: feasible and inter-observer consistent?
28. PO-0935: Correcting diffusion weighted MR images for signal pile-up and distortions near gas pockets.
29. OC-0148: Evaluation of EBRT and HDRBT for inoperable rectal cancer patients: an update of the HERBERT study.
30. OC-0621: A population based library of plans for rectal cancer: design and prospects for margin reduction.
31. PO-0713: Pathology of CTV of prostate cancer: implications for the dose to the tumor and the gland.
32. OC-0617: The PARP inhibitor olaparib is effective as radiosensitizer at 10-fold lower doses than as single agent.
33. PD-0182: Prediction of needle placement in the first fraction of cervix brachytherapy: pre-MRI plan versus expert opinion.
34. OC-0497: Feasibility study of external beam radiotherapy followed by brachytherapy in inoperable rectal cancer patients.
35. PO-0726: Pathology of CTV of prostate cancer: Implications for the dose to the tumor and the gland.
36. OC-0159: Hydrogel spacer use for prostate cancer radiotherapy - 12 month toxicity and proctoscopy results.
37. PO-0781 POTENTIAL BENEFIT OF ADAPTIVE RADIOTHERAPY DURING CHEMO-RADIOTHERAPY OF RECTAL CANCER
38. SP-0622 SHAPE VARIATION OF THE CLINICAL TARGET VOLUME IN RECTAL CANCER: COMPARISON BETWEEN SHORT-COURSE AND LONG-COURSE RT
39. OC-0068 THE NAD+ DEPLETING AGENT APO866 ENHANCES CELL DEATH WHEN COMBINED WITH RADIATION
40. A Multi-institutional Trial Of Rectal Dose Reduction During Prostate Radiotherapy Via Polyethylene-glycol Hydrogel Injection: Initial Results
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.